The Key to improved cancer therapy.
Please follow the link below to VPS for electronical registration to attend the Extraordinary General Meeting on 17 June 2013 at 14:00 hours at Parkveien 53B, Oslo. The link will be activated on Monday 27 May.
Martin Nes, a board member of the Company, as Interim Chairman of the Board of Directors and Gunnar Manum, the CFO of Clavis Pharma, to the additional position of Acting CEO
announces that the Chairman, Anders P. Wiklund, and the board members Annette Clancy and Hilde H. Steineger, have decided to resign from the Board of Directors of Clavis Pharma ASA.
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that Olav Hellebø will leave the position as CEO of the company effective 20 May by mutual agreement.